Trial Profile
A 12-week, randomised, double-blind, placebo-controlled, parallel-group multicentre study to evaluate the anti-inflammatory activity of GW842470 4mg twice daily on pulmonary hyperinflation in patients with chronic obstructive pulmonary disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GW 842470 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GSK
- 31 Jul 2021 Status changed from recruiting to completed.
- 17 May 2011 New trial record